A team of researchers at Tel Aviv University has developed a biodegradable implant that delivers a gel capable of restoring healthy nerve function to treat diseases such as Parkinson's.
The pharma giant has secured rights to an experimental therapy for celiac disease from Alvine Pharmaceuticals for $70 million in upfront payments and the promise of more money down the road.
A novel vaccine developed by a team at Weill Cornell Medical College has shown success at reducing the amount of cocaine that reaches the brain.
Projects like the moon landing and the Human Genome Project, and now possibly BRAIN, will be among the hallmarks of our civilization, the tracks we leave on the sands of time. Undertakings of this scale and scope with payouts measured in the future of mankind exceed the resources of any individual, even a Bill Gates or a Paul Allen, and the largest research institutes and corporations, though their involvement enhances the program. So what is my concern regarding BRAIN? More >>
Harlan Laboratories is investing heavily in its Indiana and California facilities, bolstering specialty research by more than doubling its number of isolators.
Pfizer hasn't decided whether to pursue additional work to seek FDA approval for the storied painkiller Remoxy, and faces a decision on the continuance of the program, sending shares of two companies with financial stakes in the candidate crashing down this morning.
The Indianapolis-based drug giant has slammed the brakes on development of enzastaurin, which failed to meet the main goal for boosting disease-free survival in a Phase III study of patients with diffuse large B-cell lymphoma.
Two years after leaving the biotech giant Genzyme, Henri Termeer has found increased demand for his expertise and personal resources from a growing crowd of startups in the Boston area and The Netherlands, he told FierceBiotech in an interview. Read more >>
In another step toward realizing the elusive potential of RNA drugs, scientists at the Scripps Research Institute have nailed down one of the mechanisms by which the gene-silencers reach their targets in the cell's nucleus.
As Sony works to build its presence in the medical device world, the Japanese giant is investing $10 million in Rainbow Medical, an Israeli incubator with portfolio companies that make stents, stimulators and other devices.